Medpage Today - "No Increase In Stroke With Anti-VEGF Tx For Eye Disorders" - Molly Walker

New York, NY
 – August 16, 2017  –– 

Recent research has found that the incidence of stroke did not increase among patients receiving anti-VEGF therapy compared with matched controls. A retrospective chart review found a smaller portion of patients receiving intravitreal injections with anti-VEGF agents suffered a stroke compared with a group of matched controls who did not receive the same therapies. Richard Rosen, MD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and director of ophthalmology research at the New York Eye and Ear Infirmary of Mount Sinai, characterized these findings as “a nice demonstration of what we’ve known clinically.” Dr. Rosen, who was not involved in the study, added that the concern with anti-VEGF treatments, which were first used in cancer patients, was that they had the potential to interfere with coagulation. “These findings are reassuring for both the physician and the patient – that this treatment is not putting them at increased risk.”

- Richard B. Rosen, MD, Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Surgeon-Director, Retina Service Chief, Director of Ophthalmology Research, New York Eye and Ear Infirmary of Mount Sinai 

Learn more